NICE guidance informed by SHTAC report on Apalutamide for treating prostate cancer

Published: 2 November 2021

Patient — Most cases of prostate cancer develop in men aged 50 or older.

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of Apalutamide with androgen deprivation therapy for treating both high-risk hormone-relapsed non-metastatic prostate cancer and hormone-sensitive metastatic cancer. The guidance was informed by a report produced by SHTAC.

NICE’s guidance recommends Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer and for treating hormone-sensitive metastatic prostate cancer.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research on cancer please visit our Research page.

Articles that may also interest you

SHTAC begins a new five-year National Institute for Health and Care Research (NIHR) funding award

NICE guidance informed by SHTAC report on Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable

SHTAC’s information specialist is co-chair of the InterTASC Information Specialists’ Sub-Group (ISSG)

Share this article Share this on Facebook Share this on Twitter Share this on Weibo